Pertuzumab + Trastuzumab + Chemotherapy for Advanced Breast Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
This phase II trial studies how well pertuzumab, trastuzumab, and paclitaxel albumin-stabilized nanoparticle formulation work in treating patients with human epidermal growth factor receptor (HER) 2-positive stage II-IV breast cancer. Monoclonal antibodies, such as pertuzumab and trastuzumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Drugs used in chemotherapy, such as paclitaxel albumin-stabilized nanoparticle formulation, work in different ways to kill tumor cells or stop them from growing. Giving pertuzumab and trastuzumab together with paclitaxel albumin-stabilized nanoparticle formulation may be a better way to block tumor growth.
Who Is on the Research Team?
Joanne Mortimer, MD
Principal Investigator
City of Hope Medical Center
Are You a Good Fit for This Trial?
This trial is for adults with HER2-positive advanced breast cancer who haven't had chemotherapy or trastuzumab for metastatic disease. They should have adequate blood counts, no serious medical conditions, and not be pregnant. Prior adjuvant therapy is allowed if it was over 12 months ago. Participants must agree to use contraception during the study.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive pertuzumab, trastuzumab, and paclitaxel albumin-stabilized nanoparticle formulation intravenously. Treatment repeats every 21 days for up to 6 courses for LABC or until disease progression for MBC.
Follow-up
Participants are monitored for safety and effectiveness after treatment completion. Follow-up occurs every 3 months for 4 years, then every 6 months for 1 year.
What Are the Treatments Tested in This Trial?
Interventions
- Paclitaxel Albumin-Stabilized Nanoparticle Formulation
- Pertuzumab
- Trastuzumab
Find a Clinic Near You
Who Is Running the Clinical Trial?
City of Hope Medical Center
Lead Sponsor
National Cancer Institute (NCI)
Collaborator